| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Aridis Pharmaceuticals Inc (NASDAQ: ARDS)
ARDS Technical Analysis
5
| As on 9th Jun 2023 ARDS STOCK Price closed @ 0.27 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.51 & Strong Sell for SHORT-TERM with Stoploss of 2.07 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ARDSSTOCK Price
| Open | 0.28 | Change | Price | % |
| High | 0.28 | 1 Day | -0.01 | -3.57 |
| Low | 0.25 | 1 Week | 0.09 | 50.00 |
| Close | 0.27 | 1 Month | 0.06 | 28.57 |
| Volume | 4016088 | 1 Year | -1.89 | -87.50 |
| 52 Week High 2.92 | 52 Week Low 0.16 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ARDS Daily Charts |
ARDS Intraday Charts |
Whats New @ Bazaartrend |
ARDS Free Analysis |
|
|
ARDS Important Levels Intraday
| RESISTANCE | 0.33 |
| RESISTANCE | 0.31 |
| RESISTANCE | 0.30 |
| RESISTANCE | 0.29 |
| SUPPORT | 0.25 |
| SUPPORT | 0.24 |
| SUPPORT | 0.23 |
| SUPPORT | 0.21 |
ARDS Forecast May 2024
| 4th UP Forecast | 3.28 |
| 3rd UP Forecast | 2.31 |
| 2nd UP Forecast | 1.72 |
| 1st UP Forecast | 1.12 |
| 1st DOWN Forecast | -0.58 |
| 2nd DOWN Forecast | -1.18 |
| 3rd DOWN Forecast | -1.77 |
| 4th DOWN Forecast | -2.74 |
ARDS Weekly Forecast
| 4th UP Forecast | 2.18 |
| 3rd UP Forecast | 1.57 |
| 2nd UP Forecast | 1.19 |
| 1st UP Forecast | 0.81 |
| 1st DOWN Forecast | -0.27 |
| 2nd DOWN Forecast | -0.65 |
| 3rd DOWN Forecast | -1.03 |
| 4th DOWN Forecast | -1.64 |
ARDS Forecast2024
| 4th UP Forecast | 8.34 |
| 3rd UP Forecast | 5.75 |
| 2nd UP Forecast | 4.15 |
| 1st UP Forecast | 2.55 |
| 1st DOWN Forecast | -2.01 |
| 2nd DOWN Forecast | -3.61 |
| 3rd DOWN Forecast | -5.21 |
| 4th DOWN Forecast | -7.8 |
Aridis Pharmaceuticals Inc ( NASDAQ USA Symbol : ARDS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ARDS Business Profile
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Address: 983 University Avenue, Los Gatos, CA, United States, 95032
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service